ETON - Eton Pharmaceuticals Inc Stock Price, Fair Value and News

3.45USD+0.33 (+10.58%)Market Closed

Market Summary

USD3.45+0.33

Market Closed

10.58%

ETON Stock Price

View Fullscreen

ETON RSI Chart

ETON Valuation

Market Cap

88.6M

Price/Earnings (Trailing)

-94.68

Price/Sales (Trailing)

2.8

EV/EBITDA

63.79

Price/Free Cashflow

ETON Price/Sales (Trailing)

ETON Profitability

Operating Margin

91.71%

EBT Margin

-2.18%

Return on Equity

-6.05%

Return on Assets

-2.95%

Free Cashflow Yield

7.69%

ETON Fundamentals

ETON Revenue

Revenue (TTM)

31.6M

Rev. Growth (Yr)

-13.94%

Rev. Growth (Qtr)

4.06%

ETON Earnings

Earnings (TTM)

-936.0K

Earnings Growth (Yr)

-347.37%

Earnings Growth (Qtr)

-289.64%

Breaking Down ETON Revenue

Last 7 days

8.2%

Last 30 days

-9.2%

Last 90 days

-24.3%

Trailing 12 Months

1.5%

How does ETON drawdown profile look like?

ETON Financial Health

Current Ratio

1.65

ETON Investor Care

Shares Dilution (1Y)

0.72%

Diluted EPS (TTM)

-0.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	24.4M	29.0M	32.8M	31.6M
2022	12.1M	16.4M	18.8M	21.3M
2021	9.1M	13.3M	17.6M	21.8M
2020	558.0K	578.0K	0	4.8M
2019	385.5K	607.0K	582.0K	959.0K
2018	0	0	0	164.0K
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Eton Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 22, 2022	brynjelsen sean	bought	21,042	2.1042	10,000	chief executive officer
Nov 17, 2021	opaleye management inc.	sold	-116,712	4.6685	-25,000	-
Nov 16, 2021	opaleye management inc.	sold	-4,560	4.8619	-938	-
Nov 16, 2021	opaleye management inc.	sold	-55,911	4.8619	-11,500	-
Nov 15, 2021	opaleye management inc.	sold	-2,400	4.8016	-500	-
Nov 15, 2021	opaleye management inc.	sold	-12,004	4.8016	-2,500	-
Nov 08, 2021	opaleye management inc.	sold	-16,234	6.101	-2,661	-
Nov 08, 2021	opaleye management inc.	sold	-305,050	6.101	-50,000	-
Nov 05, 2021	opaleye management inc.	sold	-52,935	6.3011	-8,401	-
Nov 05, 2021	opaleye management inc.	sold	-1,003,770	6.3011	-159,300	-

Which funds bought or sold ETON recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	-3.00	15.00	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-6.18	-68,438	279,342	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	1.49	-5,800	38,438	-%
Apr 19, 2024	Westside Investment Management, Inc.	added	1.93	-314,067	2,152,360	0.52%
Apr 16, 2024	Stratos Wealth Partners, LTD.	sold off	-100	-117,726	-	-%
Apr 12, 2024	CHICAGO TRUST Co NA	unchanged	-	-10,521	62,625	0.01%
Mar 11, 2024	VANGUARD GROUP INC	added	5.25	429,536	4,501,270	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-106,961	-	-%
Feb 26, 2024	Virtu Financial LLC	new	-	57,000	57,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	reduced	-71.74	-191,211	80,715	-%

Are Funds Buying or Selling ETON?

Are funds buying ETON calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ETON

No. of Funds

Unveiling Eton Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	opaleye management inc.	9.84%	2,524,887	SC 13G/A
Jan 20, 2023	opaleye management inc.	8.58%	2,170,000	SC 13G/A
Jan 28, 2022	harrow health, inc.	-	0	SC 13D/A
Jan 24, 2022	opaleye management inc.	9.69%	2,385,000	SC 13G/A
Jun 17, 2021	opaleye management inc.	15.0%	9	SC 13G/A
Feb 16, 2021	appel peter a	4.48%	1,084,329	SC 13G/A
Apr 07, 2020	opaleye management inc.	17.7%	9	SC 13G/A
Feb 14, 2020	opaleye management inc.	8.25%	9	SC 13G/A
Feb 04, 2020	brynjelsen sean	7.6%	1,374,940	SC 13G/A

Recent SEC filings of Eton Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEF 14A	DEF 14A
Apr 18, 2024	8-K	Current Report
Mar 26, 2024	S-8	Employee Benefits Plan
Mar 22, 2024	10-K/A	Annual Report
Mar 22, 2024	8-K	Current Report
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Feb 21, 2024	8-K	Current Report
Feb 15, 2024	4	Insider Trading
Feb 15, 2024	4	Insider Trading

Peers (Alternatives to Eton Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	352.0B	85.2B	-7.49%	-10.35%	10.01	4.13	6.46%	95.94%
MRK	332.3B	60.1B	-0.42%	13.93%	910.36	5.53	1.40%	-97.49%
AMGN	144.7B	28.2B	-5.70%	12.33%	21.54	5.13	7.09%	2.52%
PFE	143.3B	46.5B	-8.64%	-34.49%	-103.22	3.08	42.59%	-114.62%
GILD	81.5B	27.1B	-10.34%	-21.65%	14.4	3.01	-0.60%	23.36%
TEVA	15.4B	15.8B	-4.37%	61.97%	-26.83	0.97	6.17%	76.47%
MID-CAP
PRGO	4.3B	4.7B	1.49%	-12.83%	-340.71	0.93	4.58%	90.97%
ALKS	4.1B	1.7B	-9.36%	-12.84%	11.6	2.48	49.61%	324.78%
BHC	3.2B	8.8B	-16.97%	22.33%	-5.38	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-5.51%	13.03%	14.38	3.07	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-28.23%	-25.52%	-3.91	1.85	24.65%	80.36%
TXMD	21.5M	1.3M	-17.33%	-48.76%	-2.09	16.47	-98.14%	-109.18%
ACRX	17.8M	-	-4.55%	55.56%	-0.97	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	8.11%	-93.94%	-0.19	0.14	80.00%	43.08%
ACOR	906.7K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Eton Pharmaceuticals Inc News

Latest updates

Eton Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	4.1%	7,313,000	7,028,000	11,997,000	5,304,000	8,498,000	3,219,000	7,358,000	2,176,000	6,093,000	775,000	3,067,000	11,897,000	5,958,500	20,000	99,000	459,000	-	-	500,000	82,000	25,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	280,000	617,000	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-17.6%	3,630,000	4,403,000	9,682,000	3,346,000	6,360,000	2,018,000	4,613,000	1,327,000	5,702,500	121,000	2,893,000	10,307,000	-369,000	-8,000	-3,000	6,000	-	-	500,000	-	-
Operating Expenses	13.6%	5,623,000	4,951,000	5,799,000	5,880,000	5,298,000	4,913,000	5,953,000	6,414,000	4,388,500	5,968,000	5,218,000	4,944,000	7,051,000	4,530,000	8,878,000	2,662,000	5,042,000	3,349,000	8,054,000	2,286,000	2,374,000
S&GA Expenses	5.5%	4,576,000	4,336,000	4,674,000	5,345,000	4,354,000	4,169,000	5,263,000	4,796,000	3,707,500	3,290,000	3,228,000	4,058,000	3,650,000	2,921,000	2,610,000	2,429,000	1,624,000	1,910,000	1,589,000	1,184,000	830,000
R&D Expenses	70.2%	1,047,000	615,000	1,125,000	535,000	944,000	744,000	690,000	1,618,000	681,000	2,678,000	1,990,000	886,000	3,401,000	1,609,000	6,268,000	233,000	3,418,000	1,439,000	6,465,000	1,102,000	-
EBITDA Margin	-72.2%	0.03	0.12	0.05	-0.16	-0.31	-0.34	-0.59	-0.92	-0.03	-0.53	-0.72	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-3.8%	204,000	212,000	210,000	216,000	185,000	167,000	163,000	215,000	212,000	179,000	210,000	214,000	252,000	169,000	189,000	-	-	-	-	-	-
Income Taxes	-	247,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-247.0%	-2,009,000	-579,000	4,559,000	-2,660,000	912,000	-3,045,000	-1,558,000	-5,330,000	1,039,000	-6,094,000	-2,016,000	5,116,000	-7,687,000	-4,730,000	-9,049,000	-2,696,000	-4,965,000	-3,249,000	-7,410,000	-3,730,000	-2,910,000
EBT Margin	-132.0%	-0.02	0.07	-0.01	-0.26	-0.42	-0.47	-0.73	-1.02	-0.09	-0.61	-0.83	-	-	-	-	-	-	-	-	-	-
Net Income	-289.6%	-2,256,000	-579,000	4,559,000	-2,660,000	912,000	-3,045,000	-1,558,000	-5,330,000	1,039,000	-6,094,000	-2,016,000	5,116,000	-7,687,000	-4,730,000	-9,049,000	-2,696,000	-4,965,000	-3,249,000	-7,410,000	-3,730,000	-2,910,000
Net Income Margin	-143.5%	-0.03	0.07	-0.01	-0.26	-0.42	-0.47	-0.73	-1.02	-0.09	-0.61	-0.83	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-55.7%	387,000	873,000	7,103,000	-1,548,000	2,828,000	-1,703,000	2,450,000	1,208,000	-5,121,000	-2,952,000	-413,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.7%	31,740	31,526	30,932	23,928	25,030	21,520	23,046	23,196	27,465	26,606	29,906	31,186	26,319	11,395	14,559	17,241	17,072	13,507	18,244	23,017	28,327
Current Assets	-1.2%	26,839	27,157	26,333	19,118	20,004	16,420	19,776	18,751	23,604	25,863	29,075	30,274	24,701	9,785	12,823	15,341	15,009	12,107	16,755	21,527	27,502
Cash Equivalents	-3.1%	21,388	22,070	21,566	14,708	16,305	13,378	17,046	15,229	14,406	22,709	25,802	25,113	21,295	7,332	10,270	12,335	12,066	11,777	14,947	19,584	26,735
Inventory	-13.3%	911	1,051	816	437	557	481	531	510	550	334	1,242	1,348	1,242	1,699	1,709	1,726	380	-	-	-	-
Net PPE	52.6%	58.00	38.00	46.00	56.00	72.00	73.00	87.00	72.00	115	134	156	176	811	854	938	1,025	1,117	1,169	1,223	1,190	773
Liabilities	11.1%	16,263	14,634	14,207	12,687	11,952	10,339	9,804	9,813	9,835	10,946	9,170	9,631	10,656	10,007	7,528	6,621	6,522	1,159	1,545	3,775	2,024
Current Liabilities	56.3%	16,241	10,393	9,588	7,494	6,461	4,661	3,812	3,482	4,558	5,360	3,106	3,199	3,794	3,219	2,739	2,051	1,963	1,107	1,459	3,656	2,024
Long Term Debt	-100.0%	-	4,197	4,553	5,107	5,384	5,678	5,992	6,331	5,262	5,550	5,856	6,183	6,532	6,496	4,587	4,570	4,540	-	-	-	-
LT Debt, Current	249.4%	5,380	1,540	1,540	1,339	1,033	708	364	1,033	1,418	1,092	749	385	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-8.4%	15,477	16,892	16,725	11,241	13,078	11,181	13,242	13,383	17,630	15,660	20,736	21,555	15,663	1,388	7,031	10,620	10,550	12,348	16,699	19,242	26,303
Retained Earnings	-2.2%	-104,070	-101,814	-101,235	-105,794	-103,134	-104,046	-101,001	-99,443	-94,113	-95,152	-89,058	-87,042	-92,158	-84,471	-77,967	-73,237	-64,188	-61,492	-56,527	-53,278	-45,868
Additional Paid-In Capital	0.7%	119,521	118,680	117,934	117,009	116,187	115,202	114,218	112,801	111,718	110,787	109,769	108,573	107,797	85,838	84,977	83,836	74,720	73,822	73,208	72,502	72,153
Shares Outstanding	0.1%	25,688	25,658	25,562	25,504	25,353	25,066	25,126	25,301	24,626	25,181	24,600	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	84,700	-	-	-	51,500	-	-	-	108,800	-	-	-	64,200	-	-	-	96,600	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-55.7%	387	873	7,103	-1,548	2,840	-1,703	2,461	1,223	-5,117	-2,950	-369	3,715	-7,182	-5,094	-2,853	-7,217	-3,848	-3,215	-4,196	-6,767	-1,774
Share Based Compensation	2.7%	750	730	785	872	886	949	1,300	1,083	863	1,009	836	673	773	724	714	365	501	537	505	345	219
Cashflow From Investing	-Infinity%	-775	-	-	-	-12.00	-2,000	-761	-15.00	-3,254	-2.00	-	-	-44.00	-2.00	-	-4.00	-	-	-	-	-
Cashflow From Financing	20.1%	-294	-368	-246	-49.00	99.00	35.00	117	-385	68.00	-141	361	103	21,189	2,158	788	7,490	4,921	77.00	201	4.00	-

ETON Income Statement

2023-12-31

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total net revenues	$ 31,642	$ 21,251	$ 21,832
Cost of Sales:
Total cost of sales	10,581	6,933	2,827
Gross profit	21,061	14,318	19,005
Operating expenses:
Research and development	3,322	3,996	6,235
General and administrative	18,931	18,582	14,265
Total operating expenses	22,253	22,578	20,500
Loss from operations	(1,192)	(8,260)	(1,495)
Other income (expense):
Interest and other income (expense), net	503	(761)	(1,006)
Gain on PPP loan forgiveness	0	0	365
Gain on equipment sale	0	0	181
Loss before income tax expense	(689)	(9,021)	(1,955)
Income tax expense	247	0	0
Net loss	$ (936)	$ (9,021)	$ (1,955)
Net loss per share, basic and diluted (in dollars per share)	$ (0.04)	$ (0.36)	$ (0.08)
Weighted average number of common shares outstanding, basic and diluted (in shares)	25,645,366	25,145,657	25,207,299
License [Member]
Revenues:
Total net revenues	$ 5,500	$ 10,000	$ 19,000
Cost of Sales:
Total cost of sales	1,000	1,640	1,500
Product Sales and Royalties [Member]
Revenues:
Total net revenues	26,142	11,251	2,832
Cost of Sales:
Total cost of sales	$ 9,581	$ 5,293	$ 1,327

ETON Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Current assets:
Cash and cash equivalents	$ 21,388	$ 16,305
Accounts receivable, net	3,411	1,852
Inventories	911	557
Prepaid expenses and other current assets	1,129	1,290
Total current assets	26,839	20,004
Property and equipment, net	58	72
Intangible assets, net	4,739	4,754
Operating lease right-of-use assets, net	92	188
Other long-term assets, net	12	12
Total assets	31,740	25,030
Current liabilities:
Accounts payable	1,848	1,766
Current portion of long-term debt, net of discount	5,380	1,033
Accrued liabilities	9,013	3,662
Total current liabilities	16,241	6,461
Long-term debt, net of discount and including accrued fees	0	5,384
Operating lease liabilities, net of current portion	22	107
Total liabilities	16,263	11,952
Commitments and contingencies (Note 14)
Stockholders’ equity
Common stock, $0.001 par value; 50,000,000 shares authorized; 25,688,062 and 25,353,119 shares issued and outstanding at December 31, 2023 and 2022, respectively	26	25
Additional paid-in capital	119,521	116,187
Accumulated deficit	(104,070)	(103,134)
Total stockholders’ equity	15,477	13,078
Total liabilities and stockholders’ equity	$ 31,740	$ 25,030

About Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and dehydrated alcohol injection to treat methanol poisoning. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis; Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis; EPRONTIA, a liquid formulation of topiramate; ZONISADE, a liquid formulation of zonisamide for the treatment of partial seizures in patients with epilepsy; and Lamotrigine for Oral Suspension for the treatment of epilepsy. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

CEO	Mr. Sean E. Brynjelsen
WEBSITE	etonpharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	28

Eton Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Eton Pharmaceuticals Inc? What does ETON stand for in stocks?

ETON is the stock ticker symbol of Eton Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eton Pharmaceuticals Inc (ETON)?

As of Fri Apr 26 2024, market cap of Eton Pharmaceuticals Inc is 88.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ETON stock?

You can check ETON's fair value in chart for subscribers.

What is the fair value of ETON stock?

You can check ETON's fair value in chart for subscribers. The fair value of Eton Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eton Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ETON so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eton Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ETON is over valued or under valued. Whether Eton Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Eton Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ETON.

What is Eton Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, ETON's PE ratio (Price to Earnings) is -94.68 and Price to Sales (PS) ratio is 2.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ETON PE ratio will change depending on the future growth rate expectations of investors.